Prospective Observational Study Of Geniculate Artery Embolization For Symptomatic Knee Osteoarthritis In A Cancer Population

NCT07807943 | Recruiting

• 2 other identifiers: 2026-0111NCI-2026-06646
• Study Type: observational
• Target: 50
• Locations: 1 country
• Sites: 1

Brief Summary

To explore associations with demographics/clinical factors; assess trajectories via annual follow-up; evaluate healthcare utilization and barriers; oversample \>10-year survivors.

Conditions

Observational Study; Geniculate Artery; Embolization; Symptomatic Knee Osteoarthritis

Outcome Measures

Primary Outcomes (1)

• Numeric Rating Scale Questionnaire

  Through study completion; an average of 1 year

Interventions

SOC (Standard of care) OTHER

Patients scheduled for standard of care

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

UT MD Anderson Cancer Center

You may qualify if:

• Age ≥40 years with no upper age restriction, provided performance status permits procedural candidacy
• Symptomatic mild-to-severe knee osteoarthritis (Kellgren-Lawrence grade 2-4) on radiographs within 6 months of enrollment
• Chronic knee pain (NRS ≥4/10) for ≥3 months despite conservative treatment including steroid injections, physical therapy, and/or analgesic medications
• Inadequate candidate for or refusal of surgical intervention (e.g., total knee arthroplasty) due to cancer-related comorbidities, ongoing treatment, or participants preference
• Active cancer diagnosis (solid tumor or hematologic malignancy) confirmed at MD Anderson Cancer Center

You may not qualify if:

• Active joint infection or suspected septic arthritis
• Life expectancy \<6 months
• Prior knee arthroplasty in the index knee
• Coagulopathy or contraindications to angiography
• GFR \<30 mL/min/1.73m²
• Peripheral artery disease with stenosis or occlusion of lower extremity vasculature (relative contraindication per SIR standards, given geniculate artery collateral perfusion role)
• Radiographically normal knee joint (KL grade 0-1) - alternative etiologies should be sought
• Known active autoimmune/inflammatory arthropathy (e.g., rheumatoid arthritis, psoriatic arthritis)
• Any medical condition or clinical abnormality that, per investigator judgment, precludes safe participation in and completion of the study

Sponsors & Collaborators

• M.D. Anderson Cancer Center: lead

Study Sites (1)

UT MD Anderson Cancer Center

Houston, Texas, 77044, United States

RECRUITING

Related Links

• UT MD Anderson Cancer Center

MeSH Terms

Interventions

Standard of Care

Intervention Hierarchy (Ancestors)

Quality Indicators, Health Care; Quality of Health Care; Health Services Administration; Health Care Quality, Access, and Evaluation

Study Officials

• Nicolas J Cardenas, MD

  UT MD Anderson Cancer Center

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Nicolas J Cardenas, MD

CONTACT

713-794-4404; NJCardenas@mdanderson.org

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 2, 2026
• First Posted: September 8, 2026
• Study Start: August 26, 2026
• Primary Completion (Estimated): May 30, 2028
• Study Completion (Estimated): June 30, 2030
• Last Updated: September 8, 2026

Record last verified: 2026-09

Locations

US (1)